Fresenius Becomes Latest To Launch US Stelara Rival
Also Introduces Formycon-Partnered Otulfi Ustekinumab Biosimilar In Europe
Fresenius has become the latest firm to launch a Stelara biosimilar in both the US and Europe, bringing partner Formycon’s Otulfi version to market. But with heavy discounting already seen in the US and multiple competitors already established in the EU, will the firm be able to stand out from the crowd?
